Amphastar Pharmaceuticals (AMPH) Stock Forecast, Price Target & Predictions
AMPH Stock Forecast
Amphastar Pharmaceuticals stock forecast is as follows: an average price target of $66.00 (represents a 49.69% upside from AMPH’s last price of $44.09) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
AMPH Price Target
The average price target for Amphastar Pharmaceuticals (AMPH) is $66.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $66.00 to $66.00. This represents a potential 49.69% upside from AMPH's last price of $44.09.
AMPH Analyst Ratings
According to 1 Wall Street analysts, Amphastar Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for AMPH stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Amphastar Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 08, 2024 | David Amsellem | Piper Sandler | $66.00 | $43.30 | 52.41% | 49.69% |
| May 23, 2024 | David Amsellem | Piper Sandler | $71.00 | $43.31 | 63.93% | 61.03% |
| Mar 12, 2022 | David Amsellem | Piper Sandler | $35.00 | $34.30 | 2.04% | -20.62% |
The latest Amphastar Pharmaceuticals stock forecast, released on Aug 08, 2024 by David Amsellem from Piper Sandler, set a price target of $66.00, which represents a 52.41% increase from the stock price at the time of the forecast ($43.30), and a 49.69% increase from AMPH last price ($44.09).
Amphastar Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $68.50 |
| Last Closing Price | $44.09 | $44.09 | $44.09 |
| Upside/Downside | -100.00% | -100.00% | 55.36% |
In the current month, the average price target of Amphastar Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amphastar Pharmaceuticals's last price of $44.09. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 23, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 12, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Amphastar Pharmaceuticals's last stock rating was published by Piper Sandler on Aug 08, 2024. The company gave AMPH a "Overweight" rating, the same as its previous rate.
Amphastar Pharmaceuticals Financial Forecast
Amphastar Pharmaceuticals Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $155.65M | - | $145.71M | $140.02M | $135.02M | $120.13M | $123.47M | $120.37M | $120.89M | $112.20M | $101.66M | $103.02M | $95.92M | $83.43M | $85.81M | $84.69M | $83.38M | $80.14M | $79.05M | $79.79M | $58.39M | $56.67M |
| Avg Forecast | $219.03M | $208.85M | $195.97M | $188.32M | $192.69M | $194.67M | $170.96M | $174.65M | $173.43M | $174.63M | $137.27M | $137.27M | $127.18M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $93.42M | $44.08M |
| High Forecast | $223.65M | $213.25M | $200.09M | $192.29M | $204.51M | $194.73M | $170.96M | $174.65M | $182.05M | $174.63M | $140.16M | $140.16M | $129.86M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $112.11M | $52.89M |
| Low Forecast | $215.16M | $205.15M | $192.50M | $184.99M | $183.92M | $194.61M | $170.96M | $174.65M | $164.80M | $174.63M | $134.84M | $134.84M | $124.93M | $125.98M | $118.08M | $113.33M | $111.62M | $103.25M | $101.30M | $96.87M | $88.94M | $91.23M | $86.73M | $82.90M | $81.81M | $78.57M | $77.56M | $76.22M | $74.74M | $35.26M |
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| Surprise % | - | - | - | - | - | - | - | - | 0.90% | - | 1.06% | 1.02% | 1.06% | 0.95% | 1.05% | 1.06% | 1.08% | 1.09% | 1.00% | 1.06% | 1.08% | 0.91% | 0.99% | 1.02% | 1.02% | 1.02% | 1.02% | 1.05% | 0.63% | 1.29% |
Amphastar Pharmaceuticals's average Quarter revenue forecast for Mar 24 based on 1 analysts is $174.65M, with a low forecast of $174.65M, and a high forecast of $174.65M. AMPH's average Quarter revenue forecast represents a 12.21% increase compared to the company's last Quarter revenue of $155.65M (Dec 23).
Amphastar Pharmaceuticals EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| EBITDA | - | - | - | - | - | - | - | - | $53.98M | - | $36.90M | $33.43M | $37.83M | $23.23M | $24.82M | $36.18M | $33.67M | $43.27M | $20.31M | $13.13M | $-365.00K | $13.05M | $5.69M | $12.13M | $5.08M | $7.20M | $67.69M | $3.94M | $-5.08M | $5.52M |
| Avg Forecast | $51.89M | $49.48M | $46.42M | $44.61M | $45.65M | $46.12M | $40.50M | $41.37M | $41.08M | $41.37M | $32.52M | $32.52M | $30.13M | $19.68M | $18.44M | $24.64M | $17.43M | $16.13M | $15.82M | $7.22M | $13.89M | $14.25M | $13.55M | $11.19M | $12.78M | $12.27M | $12.12M | $2.17M | $-12.01M | $3.94M |
| High Forecast | $52.98M | $50.52M | $47.40M | $45.55M | $48.45M | $46.13M | $40.50M | $41.37M | $43.13M | $41.37M | $33.20M | $33.20M | $30.76M | $19.68M | $18.44M | $29.57M | $17.43M | $16.13M | $15.82M | $8.66M | $13.89M | $14.25M | $13.55M | $13.43M | $12.78M | $12.27M | $12.12M | $2.60M | $-9.60M | $4.73M |
| Low Forecast | $50.97M | $48.60M | $45.60M | $43.82M | $43.57M | $46.10M | $40.50M | $41.37M | $39.04M | $41.37M | $31.94M | $31.94M | $29.60M | $19.68M | $18.44M | $19.71M | $17.43M | $16.13M | $15.82M | $5.78M | $13.89M | $14.25M | $13.55M | $8.95M | $12.78M | $12.27M | $12.12M | $1.73M | $-14.41M | $3.15M |
| Surprise % | - | - | - | - | - | - | - | - | 1.31% | - | 1.13% | 1.03% | 1.26% | 1.18% | 1.35% | 1.47% | 1.93% | 2.68% | 1.28% | 1.82% | -0.03% | 0.92% | 0.42% | 1.08% | 0.40% | 0.59% | 5.59% | 1.82% | 0.42% | 1.40% |
1 analysts predict AMPH's average Quarter EBITDA for Mar 24 to be $41.37M, with a high of $41.37M and a low of $41.37M. This is -23.35% lower than Amphastar Pharmaceuticals's previous annual EBITDA (Dec 23) of $53.98M.
Amphastar Pharmaceuticals Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| Net Income | - | - | - | - | - | - | - | - | $36.17M | - | $26.12M | $26.03M | $33.91M | $15.87M | $17.35M | $24.25M | $19.97M | $29.55M | $7.77M | $5.04M | $-6.27M | $3.92M | $-192.00K | $3.95M | $-1.03M | $1.31M | $47.79M | $868.00K | $-7.25M | $893.00K |
| Avg Forecast | $61.64M | $58.54M | $52.34M | $49.87M | $50.11M | $51.24M | $40.06M | $40.11M | $47.17M | $36.04M | $29.03M | $27.58M | $20.74M | $20.47M | $18.11M | $16.84M | $19.26M | $12.49M | $10.93M | $2.77M | $7.14M | $7.29M | $7.06M | $3.64M | $3.90M | $3.47M | $1.82M | $477.40K | $-17.12M | $637.86K |
| High Forecast | $63.32M | $60.15M | $53.77M | $51.23M | $62.01M | $51.76M | $40.06M | $40.11M | $52.60M | $37.03M | $29.83M | $28.33M | $21.31M | $20.47M | $18.11M | $20.21M | $19.26M | $12.49M | $10.93M | $3.33M | $7.14M | $7.29M | $7.06M | $4.37M | $3.90M | $3.47M | $1.82M | $572.88K | $-13.69M | $765.43K |
| Low Forecast | $60.22M | $57.20M | $51.14M | $48.72M | $43.66M | $50.72M | $40.05M | $40.10M | $40.67M | $35.22M | $28.37M | $26.94M | $20.27M | $20.47M | $18.11M | $13.47M | $19.26M | $12.49M | $10.93M | $2.22M | $7.14M | $7.29M | $7.06M | $2.91M | $3.90M | $3.47M | $1.82M | $381.92K | $-20.54M | $510.29K |
| Surprise % | - | - | - | - | - | - | - | - | 0.77% | - | 0.90% | 0.94% | 1.63% | 0.78% | 0.96% | 1.44% | 1.04% | 2.37% | 0.71% | 1.82% | -0.88% | 0.54% | -0.03% | 1.08% | -0.26% | 0.38% | 26.23% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals's average Quarter net income forecast for Mar 24 is $40.11M, with a range of $40.10M to $40.11M. AMPH's average Quarter net income forecast represents a 10.89% increase compared to the company's last Quarter net income of $36.17M (Dec 23).
Amphastar Pharmaceuticals SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| SG&A | - | - | - | - | - | - | - | - | $21.74M | - | $19.00M | $20.59M | $16.10M | $16.77M | $15.73M | $17.99M | $14.70M | $15.65M | $18.69M | $19.88M | $15.82M | $15.35M | $19.95M | $14.04M | $13.98M | $14.24M | $15.42M | $19.47M | $12.72M | $12.82M |
| Avg Forecast | $34.94M | $33.32M | $31.26M | $30.04M | $30.74M | $31.06M | $27.27M | $27.86M | $27.67M | $27.86M | $21.90M | $21.90M | $20.29M | $20.10M | $18.84M | $12.49M | $17.81M | $16.47M | $16.16M | $10.93M | $14.19M | $14.55M | $13.84M | $12.95M | $13.05M | $12.53M | $12.37M | $10.71M | $30.05M | $9.15M |
| High Forecast | $35.68M | $34.02M | $31.92M | $30.68M | $32.63M | $31.07M | $27.27M | $27.86M | $29.04M | $27.86M | $22.36M | $22.36M | $20.72M | $20.10M | $18.84M | $14.99M | $17.81M | $16.47M | $16.16M | $13.12M | $14.19M | $14.55M | $13.84M | $15.54M | $13.05M | $12.53M | $12.37M | $12.85M | $36.06M | $10.99M |
| Low Forecast | $34.32M | $32.73M | $30.71M | $29.51M | $29.34M | $31.05M | $27.27M | $27.86M | $26.29M | $27.86M | $21.51M | $21.51M | $19.93M | $20.10M | $18.84M | $9.99M | $17.81M | $16.47M | $16.16M | $8.74M | $14.19M | $14.55M | $13.84M | $10.36M | $13.05M | $12.53M | $12.37M | $8.57M | $24.04M | $7.32M |
| Surprise % | - | - | - | - | - | - | - | - | 0.79% | - | 0.87% | 0.94% | 0.79% | 0.83% | 0.84% | 1.44% | 0.83% | 0.95% | 1.16% | 1.82% | 1.11% | 1.05% | 1.44% | 1.08% | 1.07% | 1.14% | 1.25% | 1.82% | 0.42% | 1.40% |
Amphastar Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $27.86M, based on 1 Wall Street analysts, with a range of $27.86M to $27.86M. The forecast indicates a 28.15% rise compared to AMPH last annual SG&A of $21.74M (Dec 23).
Amphastar Pharmaceuticals EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 4 | 2 | 1 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 5 | 5 | 9 | 6 | 4 | 4 | 7 | 4 | 11 | 14 |
| EPS | - | - | - | - | - | - | - | - | $0.68 | - | $0.54 | $0.54 | $0.70 | $0.32 | $0.35 | $0.50 | $0.42 | $0.62 | $0.16 | $0.11 | $-0.13 | $0.08 | - | $0.09 | $-0.02 | $0.03 | $1.01 | $0.02 | $-0.16 | $0.02 |
| Avg Forecast | $1.19 | $1.13 | $1.01 | $0.96 | $0.97 | $0.99 | $0.77 | $0.77 | $0.91 | $0.69 | $0.56 | $0.53 | $0.40 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.19 | $0.05 |
| High Forecast | $1.22 | $1.16 | $1.04 | $0.99 | $1.20 | $1.00 | $0.77 | $0.77 | $1.01 | $0.71 | $0.58 | $0.55 | $0.41 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.23 | $0.06 |
| Low Forecast | $1.16 | $1.10 | $0.99 | $0.94 | $0.84 | $0.98 | $0.77 | $0.77 | $0.78 | $0.68 | $0.55 | $0.52 | $0.39 | $0.39 | $0.35 | $0.36 | $0.37 | $0.24 | $0.21 | $0.18 | $0.14 | $0.14 | $0.14 | $0.09 | $0.07 | $0.07 | $0.04 | $0.04 | $0.15 | $0.04 |
| Surprise % | - | - | - | - | - | - | - | - | 0.75% | - | 0.96% | 1.02% | 1.75% | 0.81% | 1.01% | 1.39% | 1.14% | 2.58% | 0.76% | 0.60% | -0.95% | 0.57% | - | 1.05% | -0.27% | 0.45% | 28.86% | 0.50% | -0.84% | 0.40% |
According to 1 Wall Street analysts, Amphastar Pharmaceuticals's projected average Quarter EPS for Mar 24 is $0.77, with a low estimate of $0.77 and a high estimate of $0.77. This represents a 13.72% increase compared to AMPH previous annual EPS of $0.68 (Dec 23).
Amphastar Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals | $3.52 | $11.67 | 231.53% | Buy |
| PCRX | Pacira BioSciences | $17.03 | $35.00 | 105.52% | Hold |
| EOLS | Evolus | $12.63 | $24.00 | 90.02% | Buy |
| EVO | Evotec SE | $5.30 | $8.00 | 50.94% | Buy |
| AMPH | Amphastar Pharmaceuticals | $44.09 | $66.00 | 49.69% | Buy |
| ANIP | ANI Pharmaceuticals | $55.10 | $79.00 | 43.38% | Buy |
| COLL | Collegium Pharmaceutical | $30.00 | $40.50 | 35.00% | Buy |
| ALKS | Alkermes | $27.91 | $36.38 | 30.35% | Hold |
| NBIX | Neurocrine Biosciences | $123.29 | $147.35 | 19.51% | Buy |
| PBH | Prestige Consumer Healthcare | $82.67 | $89.50 | 8.26% | Buy |
| SUPN | Supernus Pharmaceuticals | $36.12 | $38.00 | 5.20% | Buy |
| DCPH | Deciphera Pharmaceuticals | $25.59 | $26.32 | 2.85% | Hold |
| PAHC | Phibro Animal Health | $23.39 | $18.67 | -20.18% | Buy |